About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker GSK · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026Mass Balance and Absolute Bioavailability of [14C]-VH4011499
NCT07934719 · HIV Infections
VH4011499, [14C]-VH4011499 (IV)
GSK
ViiV Healthcare
Phase 1Not yet recruiting18Feb 18, 2027Registry ↗
Nov 13, 2026A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Heal…
NCT07393659 · HIV Infections
Fostemsavir, Dolutegravir (DTG)/ Lamivudine (3TC)
GSK
ViiV Healthcare
Phase 3Recruiting197Sep 14, 2032Registry ↗
Nov 13, 2026A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Partici…
NCT06613698 · Liver Diseases, Alcoholic
GSK4532990, Placebo
GSK
GlaxoSmithKline
Phase 2Recruiting350Nov 26, 2027Registry ↗
Nov 13, 2026Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Dara…
NCT04246047 · Multiple Myeloma
Belantamab mafodotin, Daratumumab
GSK
GlaxoSmithKline
Phase 3Active, not recruiting494Oct 2, 2023Registry ↗
Nov 12, 2026A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult…
NCT07791043 · Liver Diseases, Alcoholic
Efimosfermin alfa, Placebo
GSK
GlaxoSmithKline
Phase 2Recruiting274Aug 11, 2028Registry ↗
Nov 12, 2026A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants…
NCT07782996 · Asthma
GSK5784283, Placebo
GSK
GlaxoSmithKline
Phase 3Recruiting370May 4, 2029Registry ↗
Nov 12, 2026A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo…
NCT07780669 · Pulmonary Disease, Chronic Obstructive
GSK5784283, Placebo
GSK
GlaxoSmithKline
Phase 3Recruiting624Jul 20, 2029Registry ↗
Nov 12, 2026A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo…
NCT07780656 · Pulmonary Disease, Chronic Obstructive
GSK5784283, Placebo
GSK
GlaxoSmithKline
Phase 3Recruiting624Jul 20, 2029Registry ↗
Nov 12, 2026A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE…
NCT07202546 · HIV Infections
VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (T…
GSK
ViiV Healthcare
Phase 2Recruiting186Oct 28, 2027Registry ↗
Nov 12, 2026A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Hea…
NCT06576271 · Systemic Lupus Erythematosus
GSK4527363, Placebo matching GSK4527363
GSK
GlaxoSmithKline
Phase 1Active, not recruiting
was recruiting
143Feb 1, 2028Registry ↗
Nov 12, 2026Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344 · Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver…
GSK4532990, Placebo
GSK
GlaxoSmithKline
Phase 2Completed
was active, not recruiting
284Jan 31, 2026Registry ↗
Nov 10, 2026A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting…
NCT07650916 · HIV
CAB ULA, RPV ULA
GSK
ViiV Healthcare
Phase 3Recruiting564Aug 13, 2029Registry ↗
Nov 10, 2026A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Fa…
NCT07545681 · Malaria, Falciparum
GSK3772701 600 mg, GSK3772701 900 mg
GSK
GlaxoSmithKline
Phase 2Recruiting
was not yet recruiting
70Oct 8, 2027Registry ↗
Nov 10, 2026A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
NCT07099898 · Neoplasms, Lung
Risvutatug rezetecan (Ris-Rez), Topotecan
GSK
GlaxoSmithKline
Phase 3Recruiting420Nov 5, 2027Registry ↗
Nov 10, 2026A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA…
NCT06694805 · HIV Infections
CAB LA + RPV LA, Oral ART
GSK
ViiV Healthcare
Phase 3Active, not recruiting326Aug 19, 2026Registry ↗
Nov 10, 2026REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal r…
NCT06041386 · Asthma
Mepolizumab, Spirometry
GSK
GlaxoSmithKline
Phase 4Active, not recruiting177Feb 12, 2026Registry ↗
Nov 10, 2026Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma
NCT03763370 · Multiple Myeloma
Belantamab mafodotin 2.5 mg/kg IV Q3Weeks + Vd (BVd), Belan…
GSK
GlaxoSmithKline
—Approved for marketing
was available
——Registry ↗
Nov 10, 2026Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Pl…
NCT02951052 · Infection, Human Immunodeficiency Virus, HIV Infections
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet
GSK
ViiV Healthcare
Phase 3Active, not recruiting618May 29, 2018Registry ↗
Nov 9, 2026First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
NCT07332455 · Neoplasms, Prostate
GSK5471713
GSK
GlaxoSmithKline
Phase 1/2Recruiting54Mar 24, 2028Registry ↗
Nov 9, 2026A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-actin…
NCT06786520 · HIV Infections
CAB LA, CAB ULA
GSK
ViiV Healthcare
Phase 1Active, not recruiting69Mar 8, 2027Registry ↗
Nov 9, 2026A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Adv…
NCT05565378 · Lung Cancer, Non-Small Cell
Pembrolizumab, Dostarlimab
GSK
GlaxoSmithKline
Phase 2Active, not recruiting351Oct 26, 2026Registry ↗
Nov 9, 2026A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Ag…
NCT05298254 · Herpes Simplex
40 µg gE-gI, 80 µg gE-gI
GSK
GlaxoSmithKline
Phase 1/2Completed504Jun 12, 2025Registry ↗
Nov 9, 2026Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
NCT04091126 · Multiple Myeloma
Belantamab mafodotin, Bortezomib
GSK
GlaxoSmithKline
Phase 1Active, not recruiting118Jun 2, 2025Registry ↗
Nov 6, 2026A Phase 3 Study to Assess the Immune Response and Safety of rMenB+OMV NZ in Primed Healthy Particip…
NCT06995430 · Meningitis
rMenB+OMV NZ vaccine
GSK
GlaxoSmithKline
Phase 3Completed312Dec 15, 2025Registry ↗
Nov 6, 2026A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Asso…
NCT06551181 · Respiratory Syncytial Virus Infections
RSVPreF3 OA investigational vaccine, Placebo (Saline soluti…
GSK
GlaxoSmithKline
Phase 3Completed2,620Apr 24, 2025Registry ↗
Nov 6, 2026A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Pa…
NCT06537414 · Chronic Hepatitis B Virus Infection, Hepatitis B
Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisir…
GSK
GlaxoSmithKline
Phase 2Active, not recruiting283May 31, 2027Registry ↗
Nov 6, 2026Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatiti…
NCT06497504 · Hepatitis B
Bepirovirsen, Placebo
GSK
GlaxoSmithKline
Phase 2Active, not recruiting153Apr 22, 2027Registry ↗
Nov 6, 2026A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI)…
NCT06433921 · Asthma, Mild Asthma
Salbutamol HFA-152a, Salbutamol HFA-134a
GSK
GlaxoSmithKline
Phase 1Recruiting84Apr 16, 2027Registry ↗
Nov 6, 2026A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary…
NCT06154837 · Pulmonary Disease, Chronic Obstructive
GSK3862995B, Placebo
GSK
GlaxoSmithKline
Phase 1Active, not recruiting127Dec 16, 2026Registry ↗
Nov 6, 2026Linerixibat Compassionate Use for Cholestatic Pruritus Adult Patients With Primary Biliary Cholangi…
NCT05448170 · Pruritus
Linerixibat
GSK
GlaxoSmithKline
—Available——Registry ↗
Nov 5, 2026A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chroni…
NCT07782970 · Nasal Polyps
GSK5784283, Placebo
GSK
GlaxoSmithKline
Phase 3Recruiting218Mar 6, 2029Registry ↗
Nov 5, 2026A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate…
NCT07747480 · Colitis, Ulcerative
Aletekitug
GSK
GlaxoSmithKline
Phase 1Recruiting
was not yet recruiting
16Mar 5, 2028Registry ↗
Nov 5, 2026A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of…
NCT07712393 · Asthma
GSK5784283
GSK
GlaxoSmithKline
Phase 1Active, not recruiting
was recruiting
24Apr 13, 2027Registry ↗
Nov 5, 2026A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participa…
NCT07704892 · Metabolic Dysfunction-associated Steatohepatitis
Efimosfermin alfa, Placebo
GSK
GlaxoSmithKline
Phase 3Recruiting380Oct 16, 2030Registry ↗
Nov 5, 2026A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Place…
NCT07701993 · Metabolic Dysfunction-associated Steatohepatitis
Efimosfermin alfa, Placebo
GSK
GlaxoSmithKline
Phase 3Recruiting1,740Jun 23, 2033Registry ↗
Nov 5, 2026A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (…
NCT07645248 · Asthma
HFA-152a, HFA-134a
GSK
GlaxoSmithKline
Phase 3Recruiting110Dec 28, 2026Registry ↗
Nov 5, 2026A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
NCT07358546 · Non-alcoholic Fatty Liver Disease
Efimosfermin alfa
GSK
GlaxoSmithKline
Phase 1Recruiting32Oct 13, 2027Registry ↗
Nov 5, 2026Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children
NCT07320716 · Diarrhoea
AltSonflex1-2-3, Menveo
GSK
GlaxoSmithKline
Phase 2Recruiting
was not yet recruiting
179Oct 16, 2028Registry ↗
Nov 5, 2026A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to C…
NCT07220109 · Respiratory Syncytial Virus Infections
RSVPreF3 OA vaccine, Placebo
GSK
GlaxoSmithKline
Phase 3Active, not recruiting750Jul 20, 2026Registry ↗
Nov 5, 2026A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to M…
NCT06920043 · Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoh…
Efimosfermin, Placebo
GSK
GlaxoSmithKline
Phase 2Recruiting42Jul 3, 2028Registry ↗
Nov 5, 2026First Time in Human Study of Long Acting VH4524184 Formulations
NCT06310551 · HIV Infections
Oral VH4524184, VH4524184 Formulation A SC
GSK
ViiV Healthcare
Phase 1Recruiting348May 28, 2029Registry ↗
Nov 5, 2026Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Par…
NCT06134362 · HIV Infections
CAB LA
GSK
ViiV Healthcare
Phase 3Active, not recruiting2,998Mar 14, 2029Registry ↗
Nov 5, 2026A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to St…
NCT05996471 · HIV Infections
VH3810109, Cabotegravir
GSK
ViiV Healthcare
Phase 2Active, not recruiting185May 27, 2026Registry ↗
Nov 5, 2026Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Stu…
NCT04954859 · Hepatitis B
Bepirovirsen, Placebo
GSK
GlaxoSmithKline
Phase 2Active, not recruiting366Jan 24, 2029Registry ↗
Nov 4, 2026A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Ad…
NCT07915791 · Pulmonary Disease, Chronic Obstructive
GSK3862995B, GSK5784283
GSK
GlaxoSmithKline
Phase 2Not yet recruiting279Mar 16, 2029Registry ↗
Nov 4, 2026Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent My…
NCT06517875 · Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis…
Momelotinib, Luspatercept
GSK
GlaxoSmithKline
Phase 2Recruiting68Mar 16, 2027Registry ↗
Nov 4, 2026A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-old…
NCT05757102 · Asthma
FF/UMEC/VI, ELLIPTA
GSK
GlaxoSmithKline
Phase 3Active, not recruiting
was recruiting
138Jan 26, 2027Registry ↗
Nov 4, 2026A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus R…
NCT05418868 · HIV Infections
Cabotegravir 200 mg/mL, CAB >=400 mg/mL
GSK
ViiV Healthcare
Phase 1Recruiting214Mar 31, 2028Registry ↗
Nov 3, 2026Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian…
NCT07694427 · Ovarian Neoplasms
Mocertatug rezetecan, Bevacizumab
GSK
GlaxoSmithKline
Phase 3Recruiting
was not yet recruiting
720Sep 6, 2029Registry ↗
Nov 3, 2026A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp End…
NCT07684599 · Neoplasms, Endometrial
Mocertatug rezetecan, Dostarlimab
GSK
GlaxoSmithKline
Phase 3Recruiting610Jul 23, 2029Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:04 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances